Oxford Immunotec (OXFD) 8.91 $OXFD Oxford Immunotec to

New Post Public Reply Private Reply Replies (0) Message Board

Jun 12, 2016 at 9:11 AM

Oxford Immunotec (OXFD) 8.91 $OXFD

Oxford Immunotec to Present at the Jefferies 2016 Healthcare Conference
Globe Newswire - Fri May 20, 10:45AM CDT
OXFORD, United Kingdom and MARLBOROUGH, Mass., May 20, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will present at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016, at 2:00 p.m. ET at the Grand Hyatt in New York, NY.
OXFD: 8.91 (-0.06)

Oxford Immunotec reports 1Q loss
Automated Insights - Tue May 03, 7:54AM CDT
ABINGDON, Britain (AP) _ Oxford Immunotec Global PLC (OXFD) on Tuesday reported a loss of $7 million in its first quarter.
OXFD: 8.91 (-0.06)

Oxford Immunotec Reports First Quarter 2016 Financial Results
Globe Newswire - Tue May 03, 6:00AM CDT
- First quarter revenue of $17.1 million, increased 24% compared to prior year period
OXFD: 8.91 (-0.06)

Oxford Immunotec Schedules First Quarter 2016 Earnings Release and Conference Call for May 3, 2016
Globe Newswire - Wed Apr 20, 10:08AM CDT
OXFORD, United Kingdom and MARLBOROUGH, Mass., April 20, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that it plans to release first quarter 2016 financial results prior to market open on Tuesday, May 3, 2016. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will host a conference call to review the Company's results at 8:00 a.m. Eastern Time the same day. The call will be concurrently webcast.
OXFD: 8.91 (-0.06)

Oxford Immunotec Takes Active Role in Raising Awareness of TB Testing and Prevention during World TB Day
Globe Newswire - Thu Mar 24, 8:00AM CDT
OXFORD, United Kingdom and MARLBOROUGH, Mass., March 24, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced the company's commitment to building awareness of TB testing and prevention during World TB Day on March 24, 2016 through its support of educational programs around the world.
OXFD: 8.91 (-0.06)

Oxford Immunotec Global appoints Patrick J. Balthrop, Sr. to board
M2 - Tue Feb 02, 3:04AM CST
Diagnostics company Oxford Immunotec Global (NasdaqGM:OXFD) revealed on Monday the election of Patrick J. Balthrop, Sr. to its board of directors.
OXFD: 8.91 (-0.06), LMNX: 20.38 (-0.42)

Patrick J. Balthrop, Sr., Former CEO of Luminex, Joins Oxford Immunotec Board of Directors
Globe Newswire - Mon Feb 01, 4:00PM CST
OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced the appointment of Patrick J. Balthrop, Sr. to its Board of Directors.
OXFD: 8.91 (-0.06), LMNX: 20.38 (-0.42)

Oxford Immunotec to Present at the LEERINK Partners 5th Annual Global Healthcare Conference
Thomson Reuters ONE - Tue Jan 26, 11:06AM CST
OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 26, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, will present at the LEERINK Partners 5th Annual Global Healthcare Conference on Wednesday, February 10, 2016, at 1:25 p.m. EST at the Waldorf Astoria in New York, NY.
OXFD: 8.91 (-0.06)

Oxford Immunotec awarded CE Mark for the T-SPOT.PRT Test for the transplantation market
M2 - Wed Dec 23, 5:03AM CST
Diagnostics company Oxford Immunotec Global PLC (NasdaqGM:OXFD) reported on Tuesday that it has received CE marking for the T-SPOT.PRT test to help transplant patients and physicians manage immune regulated conditions.
OXFD: 8.91 (-0.06)

Oxford Immunotec Announces CE Mark for the T-SPOT.PRT Test
Thomson Reuters ONE - Tue Dec 22, 3:45PM CST
OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 22, 2015 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that it gained CE marking for the T-SPOT(R).PRT test. The panel of reactive T cells (PRT) test assesses a solid organ transplant candidate's T cell response to foreign tissue, referred to as alloreactivity.
OXFD: 8.91 (-0.06)

Oxford Immunotec to Present at the 34th Annual J.P. Morgan Healthcare Conference
Thomson Reuters ONE - Fri Dec 18, 2:07PM CST
OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 18, 2015 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, and Richard Altieri, Chief Financial Officer, will present at the 34th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2016, at 2:30 p.m. PST (5:30 p.m. EST) at the Westin St. Francis on Union Square in San Francisco, CA.
JPM: 63.84 (-0.91), OXFD: 8.91 (-0.06)

Oxford Immunotec reports launch of T-SPOT.PRT test in the US transplantation market
M2 - Fri Dec 04, 5:20AM CST
Diagnostics company Oxford Immunotec Global PLC (NasdaqGM:OXFD) on Thursday announced the availability of the T-SPOT.PRT test in the US for for the transplantation market.
OXFD: 8.91 (-0.06)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ortho Molecular and HANS: Streamlining Functional Medicine

Functional Medicine Gets a Tech Boost The world of functional medicine just got a major shot in the arm, courtesy of an intriguing alliance between Ortho Molecular Products and HANS.FM. First of all, let's address the elephant in the room: clinicians in this field aren't exactly on a coffee break. They’re buried under mountains of paperwork, often spending hours just...

CURE Intl and Thoughtworks Step Into Digital Era

Pushing Paper Out, Digitizing In In a world where tech is king, why were hospitals—crucial, life-saving institutions—still bogged down by dusty folders and ink smudges? Well, not anymore for CURE International, not with Thoughtworks stepping up to the plate. This ain't just swapping paper for pixels; it's a lifeline for kids getting world-class surgical care without...

Jinko Solar Joins B20 Summit: Energy Forefront Focus

Jinko Solar's Invitation to the B20 Summit Never a dull moment in the solar space, especially when Jinko Solar, a big shot in clean energy, jumps into the spotlight at the B20 Summit in the U.S. Awash with high-profile discussions, Jinko's not just chatting—it's the only photovoltaic firm strutting its stuff in D.C. with gutsy calls for energy reform. Key Takeaways from...

Jubilant Eyes MPN Breakthrough with JBI-802 Data at ASH

Presenting the Case for JBI-802 From the bustling circus of drug development, here comes Jubilant Therapeutics, strutting their stuff with JBI-802, a dual inhibitor designed to tackle myeloproliferative neoplasms (MPNs) with a one-two punch. Now, they're set to drop some spicy deets at the 68th ASH Annual Meeting in New Orleans this December. So what's the fuss about?...

Agilyx's Q3 Update: GreenDot Shines Amid Mixed Results

Peeking into Agilyx's Financial Odyssey Just as I sip my morning coffee pondering the highs and lows of the market, here comes Agilyx ASA splashing some liquidity on the scene. The Q3 report paints the company in various shades—from solid greens to hesitant reds. Nothing like the thrill of untangling mixed results over a quiet day, huh? GreenDot's Climb to Profitability...

Inflatable Wonders Turn Christmas into a Hoot at Lowe's

Inflatables Bringing the Cheer (and Laughs) Well, it's that season again—where decorations either have us grumbling at the electric bill or chuckling at the lawn art. Lowe's has teamed up with Gemmy to serve a heaping platter of holiday giggles this year. They've rolled out a quirky lineup of inflatables that go from shivering Highland cows to dinosaurs and elves....

LG Innotek Scores Hat Trick with CES Innovation Wins

LG Innotek's Lighting Triumph Here we go again, LG Innotek just snagged their third CES Innovation Award in a row, this time for their cutting-edge vehicle lighting module, Nexlide C+. It's one for the books—breaking into the 2027 CES spotlight with innovative tech that not only grabs the eyes but could also steal the hearts of investors willing to bet on the future of...

RF MEDICAL Expands into Europe with New CE Certification

RF MEDICAL Secures CE Marking for Mi-BLATOR™ Just when you think the European medical device market's hit its saturation point, RF MEDICAL decides to kick the door open with their Mi-BLATOR™ microwave ablation system. This ain't just another plastic gadget, folks; it's got that shiny new CE marking under the European Union's Medical Device Regulation (MDR). Now, what...

BD Sets Stage for Investor Day in December 2026

BD's Investor Day: A Peek into the Future Say what you will about investor meets, but BD (Becton, Dickinson and Company) throwing its shindig on December 10, 2026, could be a highlight on the calendar if you're eyeing the medical technology sector. Scheduled in New York, this event is gearing up to be a canvas for BD's higher-ups to sketch out their roadmap. If you’re...

Centrus Energy Welcomes Nuclear Veteran to Leadership

Navigating a New Era at Centrus When you hear about seasoned veterans stepping up to the plate in the energy sector, it's time to perk up your ears. Centrus Energy (NYSE:LEU), a big player in nuclear fuel, just added Kevin Graney to their Board of Directors. This isn't your run-of-the-mill appointment; it packs nearly three decades of nuclear tech and national security...